09.28.2020

Latest news

  • Recommendations for Enhancing Blood Supply in Response to Contingencies


    The COVID-19 pandemic has proposed a new challenge to blood safety and blood supply. The flood and earthquake in some areas in recent months, as well as the earlier SARS and Wenchuan earthquakehave repeatedly reminded us that almost every public contingency, including natural disaster, accident disaster, pandemic disease and social security incident, may all impact blood collection and supply at each of every aspect or step, such as blood demand, blood collection, blood donation mobilization, as well as the operation and material supply of blood establishments. It also prompts us to realize the importance of establishing and improving the mechanism in responding to contingencies.

     

    In view of COVID-19CSBT deliberately sent letters to blood establishments and related enterprises in key epidemic areas and supporting areas, and requested for their contingency material reserve plans and recommendation lists, on the basis of their real experiences in response to the epidemic. In accordance with relevant laws and regulations, and based on the opinions, suggestions and demands gathered from blood establishments, the Working Party on Blood Equipment of CSBT (CSBT/BE) was charged the responsibility by the society to draft this recommendation. The previous experiences from handling earthquake, flood and other disasters were also considered. The document has gone through several rounds of commenting and debating among relevant institutions and experts.

     

    From the aspects of improving the plan and material reserves, this recommendation puts forward the reference opinions for blood establishments on the establishment and improvement of mechanisms in response to various contingencies.

     

    CSBT wishes to emphasize that the content of the recommendations is generated on practical experience from various institutions. They are not necessarily universally appliable, nor mandatory. Each blood establishment may set procedures according to its quality management specifications and own situation.

         

    If you find anything inappropriate or have any other opinions and suggestions, please contact with CSBT secretariat in time so that we can continually make adjustment and issue the updated edition.

     

    1. Improvement of the Contingency Plans

    Both external public contingencies and internal organizational emergencies may affect blood collection and supply in different extents. The former includes but not limited to all types of natural disasters, accidents disasters, public health incidents, and social security incidents, etc., while the latter includes all kinds of human errors, system faults of facilities and equipment, toxic/medical waste accidents, etc. The impacts of these incidents may affect many aspects, such as the changes on blood demand and supply, excess or scarcity of blood donors, the limited blood collection, detection, processing, storage and transportation, the operation of departments and equipment, the shortage of materials, and lack of qualified personnel, etc. All impacts will eventually show on the imbalance between blood demand and supply, and the lack of guarantee for effective and continuous operation of blood establishments.

     

    Leaders and staffs of blood establishments should have definite consciousnesses and full understanding on all possible risks and consequences, make forward-looking and full consideration, formulate detailed countermeasures, and implement material reserves and staffing.

     

    Leaders and relevant personnel in blood establishments should report initiatively and fully to the administrative and supervision departments, and all other bodies in concern, on the possible impacts and consequences of contingencies on blood collection and supply. They shall strive for understanding and support of relevant departments.

     

    The contingency preparation, either mechanism design or practical operation, should be an important component of organization management and quality management system. It shall be based on routine work and oriented for contingency, rather than an isolated or dissociated function.

     

    The contingency support plan of blood establishment, including material reserves and capacity construction, should take advantage of blood management information system and available resources. It is advised to achieve sharing of information, resources and capabilities-- laboratories and personnel, among blood establishments at all levels, local institutions and suppliers.

     

    2. Material Reserves

    This recommendation lists material reserves that should be considered as key objects when establishing contingency plans. Therefore, this list is not a comprehensive one but one of key points. Meanwhile, the same type of work could be carried out in different ways due to the differences in scales and economic conditions of blood establishments, so there may be several materials of the same type in the reserve list for selection.

     

    Referring to the experience of drafting units and in order to simplify the description, this recommendation unifies the contingency reserve amount of consumables to 2 months from domestic supplies and 3 months from imported ones (properly reserving time for transportation and customs clearance), in addition to routine consumption and reserve. Each blood establishment should comprehensively consider the relationship between contingency reserves and procurement/storage costs according to factors such as business volume (related to purchase batches), location (related to time of supply, and the possibility of redeployments between units), etc.

     

    Blood establishments should also comprehensively coordinate between the contingency reserve supplies and routine supplies in procurement mode, suppliers, product batches, quality inspection and validity periods, so as to reduce costs of management and operation.

     

    Contingency supplies are reserved for emergencies not for daily use. Blood establishments should strive for support from the administrative and financial departments, so as to incorporate the funds for procurement, storage and replacement of contingency supplies into the governmental budget of medical and health rescue funds for public contingencies, instead of relying on annual financial budget of blood establishments.

     

    3. Some Practical Advices

    Some of the feedbacks from CSBT members as well as other relevant contingency response materials are of great significance for reference, key points of which are now listed as below.

    The occurrence of major public contingencies may induce excessive donor and blood collections, which may cause blood oversupply, declined blood service and blood quality, or overdrawn blood collection capacity. So it is significant to estimate blood collection need by understanding and predicting the clinical demand.

    Essential procedures, such as blood screening, component separation, etc. should be backed up with other laboratories or establishments.

    In case a blood establishment could not fully run due to certain special reasons, such as epidemic prevention, power restrictions or understaffing. It is advised to identify in advance in the contingency plans key departments to which full operation must be kept, personnel must be deployed explicitly.

    Reliable contacts should be accessible for essential external support, such as contacts of water and electricity supply, manufacturers and maintenance services.

    If critical support or facility is out of service due to certain reasons, such as power failure, refrigeration failure or information system failure, alternatives such as inventory shifting, offline operation, etc. should be selected according to the predicted recovery time and these options should have been contained in the contingency plans.

    It is advised to understand adequately local supply and demand of plasma products (plasma-derived medicinal products, PDMPs), and get ready to offer professional advices when necessary, or meet extra blood demands caused by PDMPs shortage.

    The information of blood demand should be timely, explicitly and continuously published, when necessary.

    The maximum and continuous working capability of essential procedures should be clearly understood in advance.

    If employees need to work for a long time and with high load, the replacement and logistics support measures should be properly arranged to avoid adverse effects on their physical and mental health, blood service and blood safety.

     

    Appendix:

    Recommended List of Contingency Reserves

     

    Acknowledgements (in no order)

    Contributing Organizations: Wuhan Blood Center, Anhui Provincial Blood Center, Hainan Provincial Blood Center, Shanghai Blood Center, Hunan Provincial Blood Center, Beijing Red Cross Blood Center, Chengdu Blood Center, Jiangxi Provincial Blood Center, Shandong Provincial Blood Center, Tianjin Blood Center, Zhejiang Provincial Blood Center, Shanghai RAAS Blood Products Co. Ltd., Boya Bio-pharmaceutical Co. Ltd., Hunan Shengxiang Bio-Tech Co. Ltd., Chengdu Rongsheng Pharmaceutical Co. Ltd., Beijing Wantai Bio-pharmaceutical Co. Ltd., Zhongsan University Daan Gene Co. Ltd.

     

    Drafting: SUN Jun, LIU Qingning, HUANG Chengyin, ZHANG Tingxiang, HU Xiaoyu, WANG Zhengyang, DING Wenyi, ZHANG Jianwei, XIA Wei, JIANG Nizheng

     

    Translated by MAO Zhuang, ZHANG Ruoyang, LI Xueyin, FENG Chenchen, YANG Ying,

    TANG Dingjie, CHEN Xin, HU Wenjia, FENG Yasong, WANG Yawu, CHEN Xian

    Reviewed by MA Ling, ZHU Shanshan, JIANG Nizhen

     

     

    This translation has not been reviewed

    by the taskforce drifting the Recommendation.

     

    Original Document in Chinese

    https://csbt.org.cn/plus/view.php?aid=84525



    Recommendations for Enhancing Blood Supply in Response to Contingencies.pdf

    APPENDIX A:Recommendation List of Contingency Reserves.xlsx


  • Biosafety protection guidelines for blood group serology laboratories for clinical blood transfusion during the control and prevention of coronavirus disease 2019 (Second edition)

    Biosafety protection guidelines for blood group serology laboratories for clinical blood transfusion during the control and prevention of coronavirus disease 2019 (Second edition)

    Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion

     

    The Law of the People’s Republic of China on the Prevention and Treatment of Infectious Diseases stipulates that coronavirus disease 2019 (COVID-19) is a category B infectious disease and that its prevention and control should be implemented according to category A infectious diseases. To 0ensure laboratory biosafety during the control and prevention of COVID-19, the National Health Commission of the People’s Republic of China has enacted many laboratory biosafety guidelines and control and prevention plans for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1-5) and guided medical institutions (all types and at all levels) to standardize laboratory activities. With a better understanding of the disease and an accumulation of medical experience regarding clinical blood transfusion, based on the Biosafety protection guidelines for blood group serology laboratories for clinical blood transfusions during the control and prevention of COVID-19 (First edition) (6), we have formulated the second edition after taking into account the experiences of other professional branches of the Chinese Medical Association (7) and other countries regarding the control and prevention of other acute respiratory infectious diseases, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), H1N1 and H5N1 (8-9), in order to guide the blood transfusion departments (blood banks) of medical institutions (all types and at all levels) to continuously carry out effective biosafety protection.

     

     

    1. Case determination

    According to the Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) (10), patients are categorized into patients with confirmed (asymptomatic, mild, moderate, severe, and critical) or suspected COVID-19 and other patients. In these guidelines, patients in the first category are referred to as special patients, and patients in the second category are referred to as general patients.

     

     

    2. Safety principles

    2.1 Biosafety protection levels

    2.1.1 According to the Laboratory biosafety guidelines for COVID-19 (Second edition) (1), the following principles should be followed. Serological testing should be carried out in Biosafety Level 2 (BSL-2) laboratories and in a biosafety cabinet as much as possible. Individuals should be protected according to BSL-2 standards, and designated hospitals should adopt Biosafety Level 3 (BSL-3) protection standards.

    2.1.2 According to the requirements of the Announcement on issuing a working plan for further strengthening the use of convalescent plasma donated by recovered COVID-19 patients in treating COVID-19 patients (The Joint Prevention and Control Mechanism of the State Council, No. 29, 2020.) (11), plasma should be donated at designated hospitals, and BSL-2 standards and above should be adopted for personnel when collecting plasma from COVID-19 patients in the convalescent stage.

    2.2 Storage of blood components

    2.2.1 Storage of routinely used blood components should be carried out in accordance with the Technical specifications for clinical blood transfusion (National Health Commission (previous Ministry of Health) of the People’s Republic of China. No. 184, 2000.) (12).

    2.2.2 Storage of plasma from COVID-19 patients in the convalescent stage

    (1) Plasma donations should be stored at designated hospitals that have -20°C blood storage freezers to allow the separate storage of samples waiting for examination and qualified samples.

    (2) Plasma collected from convalescent COVID-19 patients should be specially labeled with COVID-19CP (convalescent plasma).

    (3) Plasma collected from convalescent COVID-19 patients (not tested) should be marked prominently and stored separately in -20°C blood storage freezers specifically for samples waiting to be tested.

    (4) Plasma from convalescent COVID-19 patients should be tested in accordance with relevant national regulations.

    (5) After passing all the relevant tests, the plasma from convalescent COVID-19 patients should be marked prominently and stored separately in -20°C blood storage freezers specifically for qualified samples.

    (6) Access to plasma samples should follow the management principle of “double person double lock” with entry and exit registration. The data should be kept for future reference.

    2.3 Thawing plasma components

    2.3.1 Operating procedures should be followed for the thawing of routinely used plasma components.

    2.3.2 Thawing of plasma from convalescent COVID-19 patients should be carried out in separate plasma thawing equipment and thawed in a 37°C water bath.

     

    3. Individual biosafety

    Biosafety Level 1 (BSL-1) protection standards include a medical surgical mask, latex gloves, uniform, medical protective cap and hand hygiene. This protection level is suitable for testing blood samples from general patients in hospitals (all types and at all levels).

     

    BSL-2 protection standards include a medical protective mask or N95 mask, latex gloves, isolation gown outside of uniform, medical protective cap and hand hygiene. Goggles may be used as appropriate (if there is a risk of splashing). This protection level is suitable for testing blood samples from patients with fever in hospitals with fever clinics.

     

    BSL-3 protection standards include a medical protective mask or N95 mask, single or double layered latex gloves (with different colors if conditions permit), face shield, protective gown outside of uniform, single or double layered medical protective cap and hand hygiene. Two layers of masks (with an outer medical protective mask and inner N95 mask) should be used when necessary. This is suitable testing blood samples from special patients at designated hospitals.

     

    Standardized procedures should be followed when putting on and taking off biosafety protective equipment. Proper hand hygiene should be followed (six-step hand washing).

     

     

    4. Workplace

    4.1 Indoor space

    4.1.1 Laboratory

    (1) General patients and patients with fever: An environment with good lighting and ventilation should be maintained. Relevant procedures in clean areas, semicontaminated areas and contaminated areas should be followed strictly, and relevant items should be stored in difference zones. Ultraviolet (UV) sterilization should conform to industrial standards (UV sterilizer GB 19258-2012). The performance of the UV sterilizer should be tested regularly. Complete records should be maintained. Accumulative usage should not exceed the prescribed time. Sterilization should be performed before and after each experiment for at least 30 min.

    (2) Special patients: A BSL-2 laboratory should be used, and relevant national regulations should be followed.

    4.1.2 Plasma donation locations should be established separately and far away from blood transfusion department laboratories (blood bank). The room should be ventilated. Relevant items should be placed according to category with clear separation between clean and dirty items, and the items should be replaced regularly. UV sterilization should conform to industrial standards (UV sterilizer GB 19258-2012). The performance of the UV sterilizer should be tested regularly. Complete records should be maintained. Accumulative usage should not exceed the prescribed time. Sterilization should be performed before and after each experiment for at least 30 min.

    4.2 Work benches and floor: Laboratory benches should be sterilized and impermeable. The benches should be disinfected once before and after each experiment. The benches and other objects (such as telephones, keyboards, computer mouse, markers, pipettes and reagent bottles) and the floor should be disinfected with wipes containing 75% ethanol or disinfectants with 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

    4.3 Blood collection boxes: Separate blood collection boxes should be used for general patients and special patients, and the boxes should be disinfected once before and after each use by wipes containing 75% ethanol or disinfectants with 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

     

     

    5. Specimen collection

    5.1 Blood specimens from general patients should be collected using BSL-1 protection standards.

    5.2 Blood specimens from patients with fever should be collected using BSL-2 protection standards, and the specimens should be labeled prominently.

    5.3 Blood specimens from special patients should be collected using BSL-3 protection standards, and the specimens should be labeled prominently.

     

     

    6. Specimen transfer

    6.1 Blood samples from general patients should be transferred according to standard procedures.

    6.2 Blood samples from patients with fever and special patients

    6.2.1 Blood samples and requisitions should be sealed in double-layered yellow safety bags first and then transferred by designated personnel.

    6.2.2 When receiving blood samples, the distance between the personnel at the blood transfusion department (blood bank) and the delivery personnel should be no less than 1 m.

    6.2.3 The personnel at the blood transfusion department (blood bank) should spray the yellow safety bags containing the blood samples and requisitions with 75% ethanol. As a disinfection measure, the outer and inner layers of the sealed bag, the tubes containing patients’ samples and the requisitions should be sprayed with 75% ethanol.

     

     

    7. Specimen centrifugation

    7.1 The test tubes containing blood samples from general patients should be placed in a centrifuge (preferably a centrifuge with biosafety functions and automatic uncapping) and processed under regular procedures.

    7.2 Blood samples from patients with fever and special patients

    7.2.1 After removal from the sealed bag, the tubes containing blood samples should be disinfected with 75% ethanol.

    7.2.2 When the tubes containing blood samples are being centrifuged (preferably a centrifuge with biosafety functions and automatic uncapping), personnel from the blood transfusion department (blood bank) should stay with the centrifuge as much as possible. The centrifuge lid should be opened within 15 min of completing the centrifugation. The tubes should be removed after they are sprayed with 75% ethanol. If no centrifuge with an automatic uncapping function is available, the tubes containing blood samples should be uncapped in a biosafety cabinet (exhausting).

    Centrifugations should be stopped immediately if accidents are suspected, such as an abnormal noise during centrifugation. Personnel at the blood transfusion department should use BSL-3 protection standards. The centrifuge should be opened within 30 min after the centrifugation has stopped and then disinfected with 75% ethanol. Insertion and removal of the centrifuge tubes into and from the rotor should be conducted in a biosafety cabinet (exhausting) when possible.

    7.2.3 It is not advisable to perform a heat elution or an ether elution on blood samples from special patients.

     

     

    8. Specimen testing

    8.1 Manual testing

    8.1.1 Separate pipettes should be used for testing blood samples from special patients.

    8.1.2 Manual blood group serological testing prior to blood transfusion, including but not limited to the identification of ABO blood group (positive and reverse typing), the identification of RhD blood group antigen, antibody screening and cross-matching tests, should be performed in a biosafety cabinet (exhausting). After loading the samples, the test tubes or microcolumn gel cards should be sealed prior to centrifugation. The centrifuge should be opened within 15 min after the centrifugation has ended. The test tubes or gel (glass beads) cards should be disinfected with 75% before being removed for reading and recording.

    8.1.3 Test tubes with blood samples should be capped with new disposable caps and disinfected with 75% ethanol.

    8.1.4 The hands of the operators should be disinfected with 75% ethanol before withdrawal from the biosafety cabinet (exhausting), and clean gloves should be used immediately after withdrawal of the hands from the cabinet.

    8.1.5 Manual testing should be minimized.

    8.2 Automatic testing

    8.2.1 Test tubes with blood samples are placed in an automatic blood group detector for testing.

    8.2.2 After testing, test tubes should be capped with new disposable caps.

     

     

    9. Posttesting procedure

    9.1 After testing, capped test tubes containing blood samples should be sealed in a double-layered yellow safety bag. After disinfecting the surface of the bag with 75% ethanol in accordance with the Technical specifications for clinical blood transfusion (National Health Commission (previous Ministry of Health) of the People’s Republic of China. No. 184, 2000, the bag should be stored separately for 7 days. After the required storage time, the bags should be autoclaved and processed in accordance with national regulations for medical waste disposal.

    9.2 All disposable test tubes, transfer tubes and microcolumn gel cards used for testing should be sealed in double-layered trash bags. After disinfecting the surface with 75% ethanol, the bags should be autoclaved and processed in accordance with national regulations for medical waste disposal.

     

     

    10. Disinfection after testing

    10.1 Reusable pipettes should be disinfected with 75% ethanol spray and wipes.

    10.2 Sampling tips and racks in the automatic blood group detector should be disinfected with 75% ethanol spray. The inside and outside surfaces of the equipment should be disinfected with wipes containing 75% ethanol or disinfectants with 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

    10.3 The inside of the biosafety cabinet (exhausting) should be disinfected with 75% ethanol spray and wipes.

    10.4 Laboratory benches, floors, centrifuges, microscopes, and other equipment and surfaces should be disinfected with wipes containing 75% ethanol or disinfectants with 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

    10.5 Upon completion of the tests, the indoor laboratory space should be disinfected with a UV light for no less than 30 min.

     

     

    11. Laboratory accident responses

    11.1 The surface of the biosafety cabinet (exhausting) contaminated by blood samples from special patients should be disinfected by disinfectant containing 5500 mg/L effective chlorine for at least 30 min. The disinfectant solution should be freshly prepared and used within 24 hours.

    11.2 For laboratory contamination caused by blood samples from special patients, the laboratory should be closed, and the contaminated areas should be covered with disinfecting wipes containing 5500 mg/L effective chlorine for at least 30 min. In the case of large spills, the laboratory can be fumigated with heated peracetic acid at 2 g/m3 overnight, or the room can be disinfected with 20 g/L peracetic acid disinfectant using an aerosol sprayer at 8 ml/m3 for 1-2 hours. The indoor humidity during fumigation should be 60%-80%.

     

     

    12. Disinfection of blood storage freezers

    12.1 Disinfection of blood storage freezers for routine storage of blood components should be carried out in accordance with the Technical specifications for clinical blood transfusion (National Health Commission (previous Ministry of Health) of the People’s Republic of China. No. 184, 2000.).

    12.2 Designated -20°C freezers for the plasma from convalescent COVID-19 patients should be defrosted once each month and disinfected with wipes containing 75% ethanol or disinfectant with 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

     

     

    13. Disinfection of plasma thawing equipment

    13.1 Disinfection of plasma thawing equipment used for the routine thawing of plasma components should follow standard operating procedures.

    13.1 Plasma thawing equipment used to thaw plasma from convalescent COVID-19 patients should be disinfected once before and after each use with disinfectant containing 500 mg/L effective chlorine (84 disinfectant diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours. If plasma from convalescent COVID-19 patients leaks from its container, the equipment should be disinfected with disinfectant containing 5500 mg/L effective chlorine for at least 30 min. The disinfectant solution should be freshly prepared and used within 24 hours.

     

     

    14. Disinfection of plasma collection equipment

    Before and after using plasma collection equipment, its surface should be wiped with wipes containing 75% ethanol or disinfectants with 500 mg/L effective chlorine (84 disinfectants diluted 100-fold). The disinfectant solution should be freshly prepared and used within 24 hours.

     

     

    15. Disinfection of records

    All paper materials for special patients, such as entry/exit lists of blood component preparations, blood transfusion application forms, blood collection forms, records of blood group serology tests, and shift switching records, should be preserved after disinfection with 75% ethanol spray.

     

     

    16. Blood sample retrieval and distribution

    16.1 Personnel retrieving blood samples at designated hospitals should retrieve blood from the blood transfusion department with a blood retrieval requisition and sterilized blood collection boxes. Personnel at the blood transfusion department (blood bank) should stay at least 1 m away from the personnel retrieving blood samples.

    16.2 Blood collection boxes specific for special patients should be used for retrieving plasma from convalescent COVID-19 patients.

     

     

    References

    1. Laboratory biosafety guidelines for COVID-19 (Second edition). Letter of the science and education office of the National Health Commission of the People’s Republic of China (No. 70, 2020. January 23, 2020).

    2. Laboratory technical guidelines for the detection and diagnosis of COVID-19 (3rd edition). January 28, 2020.

    3. Guidelines on the usage scope of common medical protective equipment in the control and prevention of COVID-19 (trial implementation). (Medical letter of the National Health Commission of the People’s Republic of China (No. 75, 2020)).

    4. Regulations for the Biosafety Management of Pathogenic Microbe Labs. Decree of the State Council of the People’s Republic of China No. 424.

    5. General biosafety standard for causative bacteria laboratories. (WS 233-2017).

    6. Biosafety protection guidelines for blood group serology laboratories for clinical blood transfusion during the control and prevention of COVID-19 (First edition). Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion. February 3, 2020.

    7. Biosafety and prevention guidelines for the clinical laboratory examination of COVID-19 (trial version 1). (Chinese Society of Laboratory Medicine. January 30, 2020).

    10. Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7). (Medical letter of the National Health Commission of the People’s Republic of China (No. 77, January 27, 2020)).

    11. Announcement on issuing a working plan for further strengthening the use of convalescent plasma donated by recovered COVID-19 patients in treating COVID-19 patients. (The Joint Prevention and Control Mechanism of the State Council, No. 29, 2020. February 28, 2020).

    12. Technical specifications for clinical blood transfusion. (National Health Commission (previous Ministry of Health) of the People’s Republic of China. No. 184, 2000. August 1, 2000).

     

     

    Note:

    *This article was funded by the scientific research project of Shanghai Science and Technology Commission (No. 17DZ2200800).

    Corresponding author units: 200233 The Sixth People's Hospital Affiliated to Shanghai Jiaotong University (Li Zhiqiang); 100005 Beijing Hospital (Gong Jiwu); 430030 Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology (Wei Qing)

    About the author: Li Zhiqiang (1962.09-), male, from Zhejiang, chief physician, postgraduate tutor, mainly engaged in the diagnosis and treatment of blood system diseases and clinical transfusion reaction research, (Tel)021-24058722, (E-mail)kcb039@126.com .cn; Gong Jiwu (1965.12-) male, from Hebei, chief technician, mainly engaged in clinical blood transfusion blood group serology and molecular biology research and quality control, (E-mail)xkgjw@139.com; Wei Qing (1965.12) Female, from Hubei, chief physician, PhD, mainly engaged in clinical blood transfusion research, ((E-mail))wei.qing@hotmail.com

    The biosafety protection guidelines for blood group serology laboratories for clinical blood transfusion during the control and prevention of COVID-19 (Version 1) was published online on February 3, 2020, by the Working Party on Clinical Transfusion Management, Chinese Society of Blood Transfusion. Authors: Juan Wang and Tongtao Tu (Tongji Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology). Proofreading: Qing Wei (Tongji Hospital affiliated with Tongji Medical College, Huazhong University of Science and Technology); Jiwu Gong (Beijing Hospital); Zhiqiang Li (The Sixth People's Hospital Affiliated with Shanghai Jiaotong University).

     

     

     

     



  • The 10th National Congress of CSBT to be held in October

    The 10th National Congress of CSBT, hosted by CSBT, jointly organized by Tianjin Society of Blood Transfusion, and undertaken by Education Committee of CSBT,Institute of Blood Transfusion (Chinese Academy of Medical Science) and Tianjin Blood Center, will be held in the city of Tianjin on October 14 -16, 2020.

     

    Key Dates

    DATE

    MATTER

    July 15,2020

    Deadline for Abstract & Paper Submission

    Aug 132020

    Deadline for Early Bird Registration

    Sept 132020

    Deadline for Regular Registration

    Sept 132020

    Deadline for Accommodation Reservation

    Sept 13 - Oct 92020

    Impending Deadline for Registration

    Oct 14 - 152020

    On-site Registration

     

    Paper & Abstract Submission

    ─ Paper Submission site is now open. Eighteen symposium topics are as follows:

    1 Blood Donation Recruitment

    10 Blood Products

    2 Blood Donation Service

    11 Clinical Transfusion, Blood Components and Blood Products Transfusion

    3 Blood Preparation, Preservation & Supply

    12 Clinical Transfusion Management

    4.TTI Screening, Pathogen Reduction

    13 New Blood Therapies, Therapeutic Apheresis, Blood Transfusion in Transplantation

    5 Immunohematology, Transplantation Matching, Platelet matching

    14 Cellular Therapies

    6 Construction and Development of Blood Establishments (Including Equipment, Logistics)

    15 Blood Establishments Management, Finance & Human Resource, etc.

    7 Informatization Construction of Blood Establishments

    16 Cultural Construction of Blood Establishments

    8 Blood Quality Management

    17 Blood Collection & Supply during COVID-19 Pandemic

    9 Laws & Regulations, Ethics and Haemovigilance

    18 Disciplinary Construction, Further Education & Scientific Research

     

    ─ Deadline for Congress Paper & Abstract Submission

    Please do submit your paper or abstract before 12:00 am. on July 16, 2020.

     

    ─ Submission Method

    Only online submission is accepted. For more information, please visit http://www.csbt.org.cn/ to find the 10th National Congress of CSBT section.

     

    Congress Registration

    Online and on-site registration are both accepted.

    After the submission of registration info under the 10th national congress of CSBT section, a reservation number will be offered and please pay the fees under the instruction. The registration is not finished until the payment is completed.

     

    Congress Contact

    ─ LI Hongwu  Editorial Office of Chinese Journal of Blood Transfusion

    Tel:    028-83373857

    Mobile:  13558807931

    Email:   cjbt_h@cjbt.cn

    ─ ZHAI Qing  CSBT Secretariat

    Tel:    010-62382363   

    Fax:    010-62382019

    Email:  congress@csbt.org.cn

    (Source: CSBT Secretariat)

    (Translated by TANG Xinyi; Reviewed by ZHU Shanshan, JIANG Nizhen)


  • The 5th Session of the 7th of CSBT Council is Held
  • YAO Ming Leads CBA staff into Blood Donation during The Pandemic
  • Foreign Friends Join Blood Donation in Shanghai during The Pandemic
  • Jiangsu Aids Hubei, Fighting COVID-19 Together for a Shared Future
  • Wuhan Blood Center Fighting the Pandemic at the Front
  • Chinese Academy of Medical Sciences Institute of Blood Transfusion (CAMSIBT) Taking Effort in Fighting the Pandemic
  • About CSBT